# Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

> **NCT00635791** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 36 (actual)

## Conditions studied

- Malignant Solid Tumour
- Renal Cell Carcinoma
- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00635791
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-10
- **Final completion:** 2012-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-06-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635791, "Phase I Study of Vorinostat and Sorafenib in Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00635791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*